The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Clinical pharmacology of platelet cyclooxygenase inhibition.
Abstract
Nonsteroidal anti-inflammatory drugs and sulfinpyrazone compete dose-dependently with arachidonate for binding to platelet cyclooxygenase. Such a process closely follows systemic plasma drug concentrations and is reversible as a function of drug elimination. Peak inhibition and extent of its reversibility at 24 hr varies consistently with individual pharmacokinetic profile. Inhibition of platelet cyclooxygenase activity by these agents is associated with variable effects on prostaglandin (PG) synthesis in the gastric mucosa and the kidney. Aspirin acetylates platelet cyclooxygenase and permanently inhibits thromboxane (TX) A2 production in a dose-dependent fashion when single doses of 0.1 to 2.0 mg/kg are given. Acetylation of the enzyme by low-dose aspirin is cumulative on repeated dosing. The fractional dose of aspirin necessary to achieve a given level of acetylation by virtue of cumulative effects approximately equals the fractional daily platelet turnover. Serum TXB2 measurements obtained during long-term dosing with 0.11, 0.22, and 0.44 mg/kg aspirin in four healthy subjects could be fitted by a theoretical model assuming identical acetylation of platelet (irreversible) and megakaryocyte (reversible) cyclooxygenase. For a given dose within this range, both the rate at which cumulative acetylation occurs and its maximal extent largely depend upon the rate of platelet turnover. Continuous administration of low-dose aspirin (20 to 40 mg/day) has no statistically significant effect on urinary excretion of either 6-keto-PGF1 alpha or 2,3-dinor-6-keto-PGF1 alpha, i.e., indexes of renal and extrarenal PGI2 biosynthesis in vivo. Whether a selective sparing of extraplatelet cyclooxygenase activity by low-dose aspirin will result in increased antithrombotic efficacy, fewer toxic reactions, or both remains to be established in prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis, H. D., Davis, J. W., Archibald, D. G., Steinke, W. E., Smitherman, T. C., Doherty, J. E., Schnaper, H. W., LeWinter, M. M., Linares, E., Pouget, J. M., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308183090703 · Cited by 1,709
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009
Patrignani, P., Filabozzi, P., & Patrono, C. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110576 · Cited by 937
Self-citationFitzGerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., Lawson, J. A., & Brash, A. R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110814 · Cited by 665
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
Patrono, C., Ciabattoni, G., Pinca, E., Pugliese, F., Castrucci, G., De Salvo, A., Satta, M. A., & Peskar, B. A. (1980) · Thrombosis Research · doi:10.1016/0049-3848(80)90066-3 · Cited by 651
Self-citationDose-Related Kinetics of Aspirin: Presystemic Acetylation of Platelet Cyclooxygenase
Pedersen, A. K., & FitzGerald, G. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411083111902 · Cited by 558
Inhibition of platelet prostaglandin synthetase by oral aspirin.
Burch, J. W., Stanford, N., & Majerus, P. W. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108941 · Cited by 558
Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation
FitzGerald, G. A., Smith, B., Pedersen, A. K., & Brash, A. R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198404263101701 · Cited by 497
Weksler, B. B., Pett, S. B., Alonso, D., Richter, R. C., Stelzer, P., Subramanian, V., Tack-Goldman, K., & Gay, W. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198304073081402 · Cited by 448
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
Whittle, B. J. R., Higgs, G. A., Eakins, K. E., Moncada, S., & Vane, J. R. (1980) · Nature · doi:10.1038/284271a0 · Cited by 392
Cited by
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.513 · Cited by 1,641
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Metadata
- Authors
- Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F., Filabozzi, P., Catella, F., Davì, G., & Forni, L.
- Venue
- Circulation
- Published
- 1985-12
- Volume
- 72
- Issue
- 6
- Pages
- 1177-1184
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2011861566
- Cited by
- 454
- References
- 25
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical pharmacology of platelet cyclooxygenase inhibition. https://app.cochat.ai/papers/10.1161/01.cir.72.6.1177
- The paper
- Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F., Filabozzi, P., Catella, F., Davì, G., & Forni, L. (1985). Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. https://doi.org/10.1161/01.cir.72.6.1177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
